Clinical Trials Logo

Clinical Trial Summary

This is a multi-center, open label, cross-over clinical study. A total of 15 subjects will be enrolled to use the IDA for every peritoneal dialysis exchange for 14 days. To participate in the study, the subjects must have current CKD5 and have been treated with PD for at least 3 months. The subjects will undergo a single peritoneal dialysis exchange procedure at the PD clinic, under supervision of the medical staff and instructed about its operation. Further exchanges will be performed by the subjects themselves at home. The study includes three periods: First period (Observational): 14-day Observational Period. Eligible subjects who sign informed consent will continue with their regular CAPD treatment while performing measurement and recording of dialysate in/out time. Second period (Interventional): 14-day interventional period, where subjects will perform dialysis exchanges using the IDA according to the below visit schedule. Third period (Follow up): 14-day follow up period, during which the study staff will call the subject once weekly to inquire about device-related SAEs and any changes to concomitant medications.


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT05342935
Study type Interventional
Source liberDi Ltd.
Contact Maya Shick
Phone 97248228090
Email maya@liberdi.com
Status Not yet recruiting
Phase N/A
Start date June 2022
Completion date March 2023

See also
  Status Clinical Trial Phase
Completed NCT05630729 - Living With CKD: An E-Learning Platform for Adolescents With CKD About the Disease and Its Management N/A
Recruiting NCT03779529 - EVOO Coratina Intervention on Lipids in Non-diabetic Hypertensive Patients Undergoing Hemodialysis (EVOOC-3H) N/A
Terminated NCT01758289 - Post Marketing Observational Study on Paricalcitol IV Administered to Venezuelan Patients N/A
Withdrawn NCT03857633 - MRI Assessment of Myocardial Fibrosis Associated With Monocyte Phenotype in End Stage Renal Failure
Completed NCT01073462 - Study to Evaluate the Effect of Intravenous (IV) Paricalcitol (Zemplar) on Cardiac Morbidity in Patients With Chronic Kidney Disease (CKD) Stage 5 Over 2 Years N/A
Completed NCT03311763 - Exercise is Medicine for Patients With CKD N/A